HER2 FISH analysis
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000508948.2
- Last updated: 2014-12-03
- Annual Review past due read more
- Test version history
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Breast neoplasm
Offered by GENETIX Centro de Investigación en Genética Humana y Reproductiva
- Cardoso et al., 2016
- Ward et al., 2013Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
- NICE, 2024UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024
- NCCN, 2023Breast Cancer, NCCN Guidelines Version 4.2022
- NCCN, 2022Breast Cancer Screening and Diagnosis, NCCN, Version 1.2022
- NICE, 2018Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
- NICE, 2018Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, NICE, 2018
- NCCN, 2014National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer (See 2022 Update)
- NICE, 2013DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: information for the public
- AHRQ, 2013Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)
- NCCN, 2011NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.